LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Long Term Outcomes in Idiopathic Inflammatory Myositis: An Observational Epidemiologic Study over 15 Years.

    Janardana, Ramya / Kn, Sangeetha / Bhat, Vasudha / Balakrishnan, Divya / Raj, John Michael / Pinto, Benzeeta / K, Chanakya / Nadig, Raghunandan / Mahadevan, Anita / Shobha, Vineeta

    Mediterranean journal of rheumatology

    2023  Volume 34, Issue 4, Page(s) 513–524

    Abstract: Background: We report a longitudinal observational cohort of idiopathic inflammatory myositis (IIM) focusing on the long-term clinical outcome and associated parameters.: Methods: IIM patients were classified as per Bohan and Peter criteria. In those ...

    Abstract Background: We report a longitudinal observational cohort of idiopathic inflammatory myositis (IIM) focusing on the long-term clinical outcome and associated parameters.
    Methods: IIM patients were classified as per Bohan and Peter criteria. In those with ≥ 24 months of follow-up; the treatment response, functional outcomes, and damage at last follow-up were recorded. Complete clinical response and clinical remission as defined by Oddis et al., was used to define outcomes at last follow-up.
    Results: The cohort consists of 175 patients, mean age 40.9 (+12.6) years, M:F 1:3.3; and the major subsets were dermatomyositis (44.6%), overlap myositis (25.7%), antisynthetase syndrome (6.3%), polymyositis (14.3%), and juvenile DM/OM (8.6%). Ninety-four patients have followed up for 24 months or more, with the median (IQR) of 65(35,100.7) months. Of them, 74.1% and 11.8% had complete and partial clinical responses respectively at the last follow-up. In our cohort 40.2% were off-steroids and 13.8% were in clinical remission at the last follow-up. Complete clinical response was associated with better functional outcomes and lesser damage as determined by HAQ-DI of 0[OR10.9; 95%CI (3.3,160)], MRS [OR 3.2; 95%CI (1.4,7.3)] and lesser MDI [OR 1.7; 95% CI (1.1,2.7)] respectively as compared to partial response (unadjusted analysis). Baseline parameters and IIM subsets did not significantly influence the functional outcome and damage. The mortality rate in our cohort is 24/175 (13.7%), the disease-specific mortality rate being 9.1%. Large majority of deaths were early, associated with active disease.
    Conclusion: We report good long-term outcomes in all major myositis subsets. Partial clinical response to treatment is associated with worse functional outcomes and damage accrual. Death occurs early in association with active disease.
    Language English
    Publishing date 2023-08-28
    Publishing country Greece
    Document type Journal Article
    ZDB-ID 3019943-8
    ISSN 2529-198X ; 2459-3516
    ISSN (online) 2529-198X
    ISSN 2459-3516
    DOI 10.31138/mjr.280823.lto
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Risk factors associated with COVID-19 in systemic lupus erythematosus: Results from a longitudinal prospective cohort.

    Patil, Abhishek / Shobha, Vineeta / Shenoy, Padmanabha / S, Chandrashekara / Kumar, Sharath / Daware, Manisha / Haridas, Vikram / Janardana, Ramya / Pinto, Benzeeta / Kodishala, Chanakya / Ramaswamy, Subramanian / S, Nagaraj / Jain, Vikramraj / Singh, Yogesh Preet / Singhai, Shweta / C, Srinivasa / Jois, Ramesh / Rao, Vijay K / Dharmapalaiah, Chethana /
    Kn, Sangeetha / Balebail, Dharmanand

    Lupus

    2023  Volume 32, Issue 4, Page(s) 560–564

    Abstract: Introduction: Patients with SLE (systemic lupus erythematosus) have a higher risk of infection due to dysregulated immune system as well as long-term use of immunosuppressants (IS). This could influence the risk of COVID-19 and its outcome.: Methods: ...

    Abstract Introduction: Patients with SLE (systemic lupus erythematosus) have a higher risk of infection due to dysregulated immune system as well as long-term use of immunosuppressants (IS). This could influence the risk of COVID-19 and its outcome.
    Methods: We conducted a longitudinal prospective study across 15 rheumatology centres during the first wave of the pandemic to understand the risk factors contributing to COVID-19 in SLE patients. During the 6 months follow-up, those who tested positive for COVID-19, their clinical course and outcome information were recorded.
    Results: Through the study period (April-December 2020), 36/1379 lupus patients (2.9%) developed COVID-19. On analysing the COVID-19 positive versus negative cohort during the study period, male gender (adjusted RR 3.72, 95% C.I. 1.85,7.51) and diabetes (adjusted RR 2.94, 95% C.I. 1.28, 6.79) emerged as the strongest risk factors for COVID-19, in the adjusted analysis. There was no significant influence of organ involvement, hydroxychloroquine, glucocorticoid dosage (prednisolone< 7.5 mg or ≥ 7.5 mg/day) or IS on the risk of COVID-19. There was only one death (1/36) among the lupus patients due to COVID-19.
    Conclusion: Traditional risk factors rather than lupus disease process or IS influenced the risk of COVID-19 in our cohort.
    MeSH term(s) Humans ; Male ; Lupus Erythematosus, Systemic/complications ; Lupus Erythematosus, Systemic/drug therapy ; Prospective Studies ; COVID-19/complications ; Longitudinal Studies ; Immunosuppressive Agents/adverse effects ; Risk Factors
    Chemical Substances Immunosuppressive Agents
    Language English
    Publishing date 2023-02-02
    Publishing country England
    Document type Journal Article
    ZDB-ID 1154407-7
    ISSN 1477-0962 ; 0961-2033
    ISSN (online) 1477-0962
    ISSN 0961-2033
    DOI 10.1177/09612033231155837
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top